XINGDA INT'L (01899) has received a comprehensive cash takeover offer from Great Trade Limited. Trading will resume on September 25th.
Xingda International (01899) issued an announcement that on September 4, 2024, it will offer to acquire Great Trade...
XINGDA INT'L (01899) announces that on September 4, 2024, Great Trade Limited has notified the company of its genuine intention (in accordance with the takeover code) to make a tender offer through Shenwan Hongyuan Group to acquire all shares not currently owned by the offeror and persons acting in concert with the offeror, at a tender offer price of HKD 1.30 per share. The tender offer price of HKD 1.30 per share is equivalent to the closing price of HKD 1.30 per share on the last trading day reported on the Stock Exchange;
As of the date of this joint announcement, the offeror and persons acting in concert with the offeror hold interests in 711 million shares, representing approximately 37.03% of the company's issued share capital.
As of the date of this joint announcement, the total issued shares of the company are 1.92 billion shares, of which the offeror and persons acting in concert with the offeror hold a total of 711 million shares (approximately 37.03% of the total issued shares). Based on the tender offer price of HKD 1.30 per share and assuming no further issuance of shares before the tender offer deadline, a total of 1.209 billion shares will be subject to the tender offer, with an estimated value of approximately HKD 15.72 billion.
The company has applied to the Stock Exchange for the trading of shares to resume from 9:00 am on September 25, 2024.
Related Articles

Financial activities nourish the fields, not delaying the farming season - HARBIN BANK is fully committed to supporting the spring farming production in 2026.

CSTONE PHARMA-B(02616): Sugelizumab Recommended Again in ESMO Guidelines [I, A] - Used for Consolidation Treatment of Stage III Non-Small Cell Lung Cancer

BATELAB (02149) releases annual performance with a profit of 122 million yuan for the year, a decrease of 26.8% year-on-year.
Financial activities nourish the fields, not delaying the farming season - HARBIN BANK is fully committed to supporting the spring farming production in 2026.

CSTONE PHARMA-B(02616): Sugelizumab Recommended Again in ESMO Guidelines [I, A] - Used for Consolidation Treatment of Stage III Non-Small Cell Lung Cancer

BATELAB (02149) releases annual performance with a profit of 122 million yuan for the year, a decrease of 26.8% year-on-year.

RECOMMEND

Pace Of Public Fund Issuance Slows, Hong Kong Stocks Become A Primary Focus
24/03/2026

Jensen Huang In‑Depth Interview: Token Economy Surge, AI Computing’s Share Of GDP To Multiply One Hundredfold, NVIDIA’s $10 Trillion Valuation Inevitable
24/03/2026

Are U.S.‑Iran Talks Genuine? At Minimum, Wall Street Read A Clear Signal From Trump’s Five‑Minute Rally
24/03/2026


